Neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's diseases affect millions of people. These disorders are age-dependent, progressive and, at present, incurable. A practical and relevant model is needed to investigate the molecular determinants of these debilitating diseases. Mammalian models are often prohibitively expensive, time-consuming and very complex. Given the highly conserved neurological pathways between mammals and invertebrates, Caenorhabditis elegans has emerged as a powerful tool for the investigation of the pathophysiology of these disorders. We describe recent findings in this area and show how C. elegans is being used to broaden our knowledge of human neurodegenerative diseases.
Introduction to neurodegenerative diseases
As human life expectancy continues to increase, a major challenge we face is that of neurodegenerative disorders such as PD (Parkinson's disease) and AD (Alzheimer's disease) and polyglutamine-expansion disorders. A common feature of neurodegenerative diseases is the loss of neurons or loss of neural activity owing to the accumulation of protein aggregates within the nervous system [1] . PD affects between 1 and 4 % of the population over 65 years of age. PD neurodegeneration occurs predominantly in dopaminergic neurons as a result of the formation of large intracellular inclusions, called Lewy bodies, containing the protein α-synuclein [2, 3] . It is unknown how these α-synuclein aggregates occur, although certain mutations and multiplication of the α-synuclein gene locus have been associated with familial PD [4, 5] .
AD is the most common form of dementia, affecting more than 30 million people worldwide. The pathology of AD is the accumulation of extracellular senile plaques, consisting predominantly of the amyloid β-peptide, and intracellular neurofibrillary tangles, consisting largely of the microtubuleassociated protein tau [6, 7] . Again, it is not fully understood how tau becomes aggregated in sporadic forms of AD. Additionally, pathological tau is hyperphosphorylated, but it is unknown how or whether this leads to neurotoxicity [8, 9] .
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glutamine repeats correlates directly with the severity of the disease and the rate of progression of neurological symptoms [10] . It appears that it is the polyglutamine tract that causes the increased propensity for aggregation and that the toxicity of polyglutamine proteins is possibly due to the disruption of general protein-folding homoeostasis, 'proteostasis', within the cell [11] .
Caenorhabditis elegans as a model organism
In order to better understand the pathophysiology of these neurodegenerative disorders, in vitro assays and model organisms needed to be developed. Studies on unicellular organisms such as yeast or bacteria, as well as mammalian cell culture, have been carried out [12] [13] [14] . However, these systems completely remove the possibility of observing any systemic effects present in a whole organism. Highthroughput genetic or pharmacological screens using rodent models are very expensive and time-consuming and are limited to a small number of animals per treatment. Maintaining constant conditions within each experiment, never mind between different research groups, is also very difficult with such complex organisms. Additionally, in cases such as PD, the experimenter is looking for loss of dopaminergic neurons which are located deep inside the midbrain in the substantia nigra pars compacta, comprising many thousands of cells and thus making in vivo monitoring of macromolecular processes prohibitively difficult. Invertebrate models such as C. elegans are therefore attractive as they offer much greater experimental flexibility and control in a better defined genetic and physiological background.
C. elegans is a small transparent organism consisting of 959 somatic cells, all of which are visible with a microscope throughout the life of the animal. A short generation time and lifespan of approx. 3 weeks, both hermaphroditic and sexual reproduction and a simple genome (five autosomes and one sex chromosome) make it an ideal genetic model [15] . Additionally, being the first multicellular organism to have its genome sequenced and the discovery of RNAi (RNA interference) in C. elegans made it ideal for highthroughput functional genetic screens [16] . Importantly for the investigation of disorders of the nervous system, the morphology and synaptic connections of its 302 neurons have been well described [17, 18] . This makes in vivo screening of morphological or degenerative changes in all neurons, or in discrete subsets of neurons (dopaminergic or glutamatergic cells for example [19] ), straightforward.
An important consideration for the usefulness of C. elegans is its relevance to human disease. Over half of the C. elegans genes have human homologues, and many human genes have been shown to compensate for mutant C. elegans genes; for example, the AD-related neuronal protein presenilin can rescue the neurite morphological defects caused by loss of the homologous nematode protein SEL-12 [20] . Studies of other neuronal proteins also show functional conservation between mammals and C. elegans; for example, mammalian Munc18 and nematode UNC-18 [21] . Work in this area from our laboratory also exemplifies the genetic power of C. elegans to illustrate gross behavioural changes caused by the introduction of specific point mutations in a neuronal protein [22, 23] .
The potential value of using C. elegans as a model for neurodegenerative disorders is clear and various studies with this organism have now been carried out. To date, these have centred on the expression of exogenous neurodegenerative proteins in the nematode and forward genetic screens have then been performed to find genetic modifiers of the resultant pathology. In the present paper, we summarize work in this field.
Tauopathies
As mentioned above, tau is a microtubule-associated protein involved in the polymerization and stabilization of the microtubule network. Aggregates of hyperphosphorylated tau form neurofibrillary tangles in many neurodegenerative disorders such as AD, Pick's disease, corticobasal degeneration, Down's syndrome and FTDP-17 (frontotemporal dementia with parkinsonism chromosome 17 type) [8] . For the latter, certain mutations in tau have been described that lead to reduced microtubule binding and an increased propensity to aggregate (FTDP-17 mutant tau) [9] . These mutants, along with wild-type tau, were expressed in all neurons of the nematode under the control of the panneuronal promoter P aex−3 . Resultant transgenic animals displayed an unco-ordinated (Unc) phenotype, which was due to a presynaptic defect and was more pronounced in the FTDP-17 mutant lines [24] . These lines also gave rise to increased insoluble tau and led to degeneration of neurons. A genome-wide RNAi screen was performed on these transgenic nematodes carrying FTDP-17 tau. This resulted in the identification of 75 genes that exacerbated the tau-induced Unc phenotype. Of these, 60 showed tau-dependency, whereas 15 increased the Unc phenotype independent of tau. Reassuringly, six genes had been implicated previously in tau-mediated pathology in other models that are associated with tau hyperphosphorylation, proteolysis and neurotransmission. Most genes identified fell into categories of phosphorylation [e.g. GSK3B (glycogen synthase kinase 3β)], protein folding and stress response [e.g. HSP70 (heat-shock protein 70)], nucleic acid function (e.g. sir-2.3), proteolysis [e.g. CTSE (cathepsin E)] or neurotransmission (e.g. Munc13-4) [24] . Most of these genes had not previously been associated with tauopathy and are consequently potentially interesting for future research.
The RNAi screen described above involved the expression of tau mutants in the nervous system of Bristol N2 nematodes. The neurons of this nematode strain, and indeed most strains, are recalcitrant to RNAi [25] . As such, some potential 'hits' may have been missed due to insufficient knockdown of the target mRNA. To address this, the authors performed random mutational screens on the same transgenic animals using a chemical mutagen. This resulted in the identification of 13 mutants which suppressed the Unc phenotype and the identification of sut-1 and sut-2 (suppressor of tauopathy) genes [26, 27] . To prevent the tauinduced Unc phenotype SUT-1 requires the activity of UNC-34, a protein required for correct neuronal cell migration and axonal guidance. sut-2 encodes a CCCH zinc finger protein that is expressed primarily in the nucleus of neuronal cells and binds the HOOK family protein, ZYG-12, a protein involved in microtubule attachment of membrane compartments. Neither of these genes had previously been associated with tauopathies and may present novel therapeutic strategies in the future.
Synucleinopathies
A large proportion of the neurodegeneration studies using C. elegans have focused on overexpression of either wildtype or familial Parkinson mutant forms of α-synuclein [28] . C. elegans does not contain an obvious homologue, but expression of exogenous protein appears to mimic the pathology seen in higher organisms. As α-synucleincontaining Lewy bodies most severely affect dopaminergic neurons in mammals, human α-synuclein has been expressed in nematodes under the control of the promoter region of the dopamine transporter gene (P dat−1 ). This leads to loss of dopaminergic cell bodies and dendrites and an accumulation of α-synuclein in the remaining cell bodies [29, 30] . C. elegans contains only eight dopaminergic neurons, which makes scoring the health of these much easier than in a mammalian or fruitfly model. Additionally, nematodes expressing α-synuclein fail to modulate their locomotion in response to food. Classically, dopaminergic neurons of nematodes control a slowing down of the animal when it encounters food. Expression of α-synuclein, either in motor neurons or pan-neuronally, results in defective motor outputs as assayed by locomotion rate. Microarray analysis of C. elegans genes up-regulated in response to α-synuclein expression reveals the involvement of the ubiquitin-proteasome system as well as nine histones and many mitochondrial genes. These results were consistent with proteomic studies from mammalian cells [31] .
Screens in yeast have made use of this model for synucleinopathy to validate findings in a multicellular context. α-Synuclein overexpression leads to a block in ER (endoplasmic reticulum)-Golgi trafficking [32] . This is relieved when various members of exocytotic machinery are co-expressed, for example YPT1p (yeast Rab1 homologue) and YKT6p [yeast ER-Golgi vesicular SNARE (soluble Nethylmaleimide-sensitive fusion protein-attachment protein receptor) protein]. Co-expression of Rab-1 with α-synuclein in C. elegans dopamine neurons led to an increase in neuronal health compared with α-synuclein alone.
In order to circumvent the potential problem of RNAi recalcitrance in C. elegans neurons, groups have performed RNAi forward genetic screens using α-synuclein expressed in muscle cells [33] . Fluorescent protein-tagged α-synuclein formed age-dependent inclusions throughout the cytoplasm of cells. Whereas muscle cells are large and easy to score, this approach does allow the possibility of missing certain neuron-specific genes involved in synucleinopathy. Van Ham et al. [33] used a genome-wide screen and, of the 80 genes pulled out, found genes involved in ER-Golgi transport and the vacuolar (lysosome) compartment to be particularly well represented. This seems to fit well with the yeast screens mentioned above. Also, various genes found to regulate lifespan were found, for example sir-2.1, which is very similar to and may functionally mimic sir-2.3 found in tauopathy studies [24] . Comparative studies such as these may identify general regulators of protein aggregation disorders. An elegant study by Hamamichi et al. [34] co-expressed a chaperone, TOR-2, along with α-synuclein in body wall muscles to create a system where more subtle changes in α-synuclein misfolding may be observed in an RNAi screen. Although there is no nematode α-synuclein homologue, other familial PD markers are represented and these defined the subset of genes to be investigated in this RNAi screen. Knockdown of 20 genes strongly enhanced α-synuclein misfolding. In this resultant set, orthologues of known PD markers were present, thereby validating the results. Once again, ER-Golgi transport genes were discovered such as F55A4.1, a vesicle SNARE protein similar to SEC22. The nematode homologue of the yeast vacuolar sorting protein Vps41, vps-41, is also represented in addition to several genes involved in proteasomal degradation pathways. ER-Golgi and lysosomal trafficking proteins, in addition to protein degradation pathways, appear to be important in preventing protein aggregation disorders.
The use of RNAi-sensitive strains offers another tool for screening potential neurodegenerative genes. For example, mutations in the RNase encoded by the gene eri-1 sensitizes the animals to treatment with interfering RNAs. This allows α-synuclein expression and knockdown of target gene expression in the more relevant setting of neurons. In a recent study in an eri-1 mutant background, the knockdown of ten neuronally expressed genes caused severe growth or motor abnormalities owing to α-synuclein expression [35] . Four genes were related to the endocytic pathway, again supporting previous reports.
Polyglutamine neurotoxicity
Expression of glutamine-expanded huntingtin in the nervous system of C. elegans leads to neurodegeneration as in mammalian models, mimicking that seen in Huntington's disease patients. Studies to identify proteins involved in this have shown that mutation of the pqe-1 gene exacerbates the neurodegeneration, whereas overexpression of pqe-1 protects animals from the effects of polyglutaminehuntingtin aggregation [36] . Expression of a polyglutamineexpanded yellow fluorescent protein in the muscles of C. elegans shows a similar age-dependent accumulation of aggregated proteins. An RNAi screen was performed, and 186 genes were found to affect protein aggregation [37] . Many of these were genes associated in some way with protein synthesis and proteasomal degradation. Surprisingly, only one gene, vha-1, was found in this screen and the α-synuclein screen by the same group. This potentially indicates some specificity between different aggregation disorders. Indeed, HSP70 was identified in this screen, whereas it had no apparent effects on α-synuclein aggregation.
Conclusions and future perspectives
C. elegans has a well-characterized and easily accessible nervous system. The morphology, location and connectivity of each of its 302 neurons are well defined. Combined with the wide array of genetic tools available to the C. elegans biologist, these properties make it amenable to high-throughput genetic and pharmacological screens [38] . Functional conservation of physiological pathways, particularly within the nervous system, between nematodes and mammals allows for the possibility of highly relatable results to human pathologies [28, [39] [40] [41] .
As summarized above, the conservation of genetic interactors of tauopathy, synucleinopathy and polyglutamine-aggregation disorders are not very clear as there appears to be little overlap between genes pulled out from these screens. This may have been complicated by trying to compare muscle-and nervous system-based assays. Further screens in the nervous system may shed light on some conserved pathways involved in these aggregation diseases. Also, expansion of potential target proteins involved in neurodegeneration will be of great interest. One such protein, CSP (cysteine string protein), is a synaptic chaperone protein with an essential role in preventing presynaptic neurodegeneration [42] . CSP mutant Drosophila exhibit a semi-lethal phenotype, whereas CSP-knockout mice show age-dependent neurodegeneration, owing to a synaptic accumulation of electron-dense debris and premature death [42, 43] . Surprisingly, in mice, overexpression of α-synuclein ameliorates the CSP-knockout-dependent neurodegeneration, whereas deletion of α-synuclein exacerbates the phenotype, suggesting a link between CSP and α-synuclein [44] . CSP is a DNA-J domain-containing protein, allowing recruitment and activation of Hsc70 (heat-shock cognate 70) and, as its name suggests, contains a string of cysteine residues that are heavily palmitoylated and allow attachment to vesicle membranes [45] [46] [47] .
The discovery of the essential role of CSP in preventing neurodegeneration and its functional overlap with α-synuclein have increased the urgency for further study of this protein in nematodes. C. elegans contains a single CSP homologue, dnj-14, the knockout of which leads to very similar phenotypes to those described above in higher animals. Nematodes lacking DNJ-14 are viable, but show increased mortality, with mutant animals living approximately half as long as wild-type. Mutant nematodes showed a significant reduction in locomotion, which was highly age-dependent and analogous to the lethargic phenotypes in other models. Expression of a pan-neuronal fluorescent marker showed a wild-type appearance in young animals; however, after a few days gross changes occur and neuronal health is severely reduced, coinciding with the loss of locomotor function (J.R. Johnson, R.C. Jenn, J.W. Barclay, R.D. Burgoyne and A. Morgan, unpublished work). As described, previous studies have identified candidate therapeutic targets for their particular disease models. Future genetic screens using the C. elegans dnj-14 −/− model may lead to the discovery of pathways that are not diseasespecific and thus identify targets of more general therapies for neurodegenerative disorders.
